VRPX (Virpax Pharmaceuticals) Market Cap: $0.01 Mil (As of Jun. 26, 2026)


What is Virpax Pharmaceuticals Market Cap?

Virpax Pharmaceuticals VRPX Market Cap is $0.01 Mil as of Jun. 26, 2026.

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Virpax Pharmaceuticals's share price for the quarter that ended in Dec. 2024 was $9.4975. Virpax Pharmaceuticals's Shares Outstanding (EOP) for the quarter that ended in Dec. 2024 was 0.60 Mil. Therefore, Virpax Pharmaceuticals's market cap for the quarter that ended in Dec. 2024 was $5.66 Mil.

Virpax Pharmaceuticals's quarterly market cap increased from Jun. 2024 ($1.47 Mil) to Sep. 2024 ($3.40 Mil) and increased from Sep. 2024 ($3.40 Mil) to Dec. 2024 ($5.66 Mil).

Virpax Pharmaceuticals's annual market cap declined from Dec. 2022 ($7.31 Mil) to Dec. 2023 ($3.76 Mil) but then increased from Dec. 2023 ($3.76 Mil) to Dec. 2024 ($5.66 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Virpax Pharmaceuticals's Enterprise Value for Today is $-1.50 Mil.


Virpax Pharmaceuticals  (OTCPK:VRPX) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Virpax Pharmaceuticals Market Cap Related Terms


Virpax Pharmaceuticals Market Cap Historical Data

* Premium members only.

The historical data trend for Virpax Pharmaceuticals's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Virpax Pharmaceuticals Market Cap Chart

Virpax Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Market Cap
Get a 7-Day Free Trial 0.00 40.30 7.31 3.76 5.66

Virpax Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.76 5.01 1.47 3.40 5.66

VRPX vs SYGGF, SCPX, LADX: Market Cap Comparison

For the Biotechnology subindustry, Virpax Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Virpax Pharmaceuticals Market Cap vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Virpax Pharmaceuticals's Market Cap distribution charts can be found below:

* The bar in red indicates where Virpax Pharmaceuticals's Market Cap falls into.



Virpax Pharmaceuticals Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Virpax Pharmaceuticals's Market Cap for the fiscal year that ended in Dec. 2024 is calculated as

Market Cap (A: Dec. 2024 )=Share Price (A: Dec. 2024 )*Shares Outstanding (EOP) (A: Dec. 2024 )
=$9.4975*0.596
=$5.66

Virpax Pharmaceuticals's Market Cap for the quarter that ended in Dec. 2024 is calculated as

Market Cap (Q: Dec. 2024 )=Share Price (Q: Dec. 2024 )*Shares Outstanding (EOP) (Q: Dec. 2024 )
=$9.4975*0.596
=$5.66

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Market Cap →
What does a Market Cap of $0.01 Mil mean?
Virpax Pharmaceuticals (VRPX) has a Market Cap of $0.01 Mil as of Jun. 26, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Virpax Pharmaceuticals and its competitors.
Is Virpax Pharmaceuticals' Market Cap too high?
Virpax Pharmaceuticals' current Market Cap is $0.01 Mil. The Biotechnology industry median Market Cap is 113.83. Virpax Pharmaceuticals' value of $0.01 Mil is 100% below this industry median.
How does Virpax Pharmaceuticals' Market Cap compare to SYGGF and SCPX?
Virpax Pharmaceuticals' Market Cap of $0.01 Mil can be compared against companies in the Biotechnology industry. The industry median Market Cap is 113.83. Virpax Pharmaceuticals' value of $0.01 Mil is 100% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 113.83, based on 1,431 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Virpax Pharmaceuticals's current Market Cap of $0.01 Mil is 100% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Virpax Pharmaceuticals and its competitors. For the Biotechnology industry, the median Market Cap is 113.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Virpax Pharmaceuticals's current Market Cap is $0.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Virpax Pharmaceuticals stock overvalued right now?
Virpax Pharmaceuticals (VRPX) has a current Market Cap of $0.01 Mil. The current Market Cap is $0.01 Mil and 100% below the Biotechnology industry median of 113.83. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Virpax Pharmaceuticals (VRPX), the current Market Cap is $0.01 Mil as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Virpax Pharmaceuticals Business Description

Address 1055 Westlakes Drive, Suite 300, Berwyn, PA, USA, 19312
Virpax Pharmaceuticals Inc is a preclinical stage biopharmaceutical company. The company is focused on developing pharmaceutical product candidates for pain management. Its product portfolio includes Topical metered-dose spray; Liposomal in Hydrogel encapsulation; and Enkephalin Intranasal spray.